Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process a new industry-wide trend.
You became vice president and general manager of GSK Switzerland in March 2015, at the same time as the three-part transaction with Novartis was finalized. What mandate were you set regarding the development of GSK’s business in Switzerland?
New product development is central to GSK’s global strategy. Last year, we generated GBP 2 billion (USD 2.67 billion) of sales from new products, higher than any other major pharmaceuticals group in terms of proportion to total sales.
